Skip to content

Single incision sling versus Bulkamid in treating SUI

A non-randomized prospective observational cohort trial comparing the single-incision-sling (TVT Altis ®) versus Bulkamid®-injections in the treatment of female stress urinary incontinence

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON23096
Enrollment
224
Registered
2021-03-22
Start date
2021-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress urinary incontinence

Interventions

• Single incision mid-urethral sling (Altis) • Urethral injection treatment (Bulkamid)

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Predominant stress urinary incontinence (e.g. on a weekly basis more incontinence episodes related to physical exercise, coughing or sneezing, as compared to incontinence associated with a feeling of urgency). • The stress urinary incontinence is confirmed during physical examination, stress test or urodynamic assessment. • Moderate to severe incontinence as identified by use of the Sandvik score • Women should be able to understand the Dutch language both verbally as well as in writing.

Exclusion criteria

Exclusion criteria: • A post voiding bladder volume of more than 100 ml, as determined by bladder catheterisation or ultrasound (Bladderscan®) • History of anti-incontinence surgery • Genital prolapse Stage 2 (Ba >0) or more according to the POP-Q classification • Patients desire for future pregnancy and childbirth • Co-morbidity which is associated with increased surgical risks, for instance women with ASA 3 or 4 classification > up to the physician to decide. • History of recurrent lower urinary tract infection (> 3 times/year) • History of current major psychiatric illness, as subjectively assessed by the physician • History of chronic or current neurological disease, as subjectively assessed by the physician • Poor cognitive function, as subjectively assessed by the physician

Design outcomes

Primary

MeasureTime frame
To record patient satisfaction to treatment of stress incontinence (Patient Global Impression of Improvement) at 1 year follow up after Altis® procedures administered under conscious sedation with local infiltration or Bulkamid (PAHG).

Secondary

MeasureTime frame
1. Subjective cure of stress incontinence at 3 months, 1 year and 5 years after surgery 2. Objective cure of stress incontinence at 3 months, 1 year and 5 years after surgery 3. Complications during and after the procedure 4. Pain scores postoperative 5. Cost-effectiveness of the treatment

Contacts

Public ContactNienke Osse

Isala

nienke.osse@gmail.com0615178217

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)